EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Bluelinea SA (ALBLU) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Bluelinea SA €0.33, price €0.14, upside +136.8%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · FR · ISIN FR0011041011

BS Thin data Sep 23, 2026

Bluelinea SA

ALBLU · PA

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value €0.3315 · Strongly undervalued (+137%)
!Quality 30/100
!Expensive Growth (revenue 5y +8.8 %/yr)
!Loss-making · -13.6% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (2/11)
!Narrow moat 13/100
!Insider activity 40/100
!Evidence only low, so the estimate is less certain
Watch Bluelinea SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.01 €0.1400 Fair Value €0.3315 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €0.1400 – €3.01 · fair‑value band €0.2210 – €0.4420 · the €0.1400 price screens below the €0.3315 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Bluelinea in your weekly email

Every Wednesday you see whether Bluelinea is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bluelinea provides health services for elderly and disabled people in France. It offers seniors and home services, including day and night family, and elder support related services.

Show more

Bluelinea provides health services for elderly and disabled people in France. It offers seniors and home services, including day and night family, and elder support related services. The company also provides connected establishments services that protects residents while assisting caregivers and staff in shared accommodation between seniors, serviced residences, EHPADs, specialized disability centers, and health establishments. Bluelinea was incorporated in 2006 and is headquartered in Versailles, France.

Stock analysis

Bluelinea SA (ALBLU) currently trades at €0.1400, while our model-based Fair Value estimate is €0.3315, implying the stock looks roughly 57.8% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: €0.2210 (bear) to €0.4420 (bull), the price of €0.1400 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Bluelinea SA reported revenue of €10.4M in FY2025 versus €7.5M in FY2021, a compound +8.4%/yr. Reported net income was −€1.5M in FY2025.

Key figures

Market cap €6.4M · P/S ratio 0.58 · EPS (TTM) €−0.0700 · Net margin −14.5% · Return on equity −70.6% · Return on assets (EBIT) −17.6% · Operating margin −11.8% · Revenue (TTM) €11.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 74% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 137%, ALBLU screens cheaper than that median.

Fair Value models

Bear €0.2210 Fair Value €0.3315 Bull €0.4420
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA €0.3200 €0.4500 €0.5700 67
NCAV (Graham) €0.0700 €0.0900 €0.1300 54
All 2 models by family
Multiples
EV/EBITDA €0.3200 €0.4500 €0.5700 67
Asset-Based
NCAV (Graham) €0.0700 €0.0900 €0.1300 54

Open the full fair value analysis →

Notify me when ALBLU reaches fair value

Put ALBLU on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 30/100

Of which business quality 31 · Market factors (momentum, volatility) 15

Profitability 37
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 27
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +106.9% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−46.0% (2020) → −12.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ALBLU, get fair value alerts →

Compare Bluelinea SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside +126% · Top 25%
Profitability
Return on assets −9% · Below median
Net margin (TTM) −14% · Below median
Operating margin (TTM) −12% · Below median
Growth and dividend
Revenue growth −9% · Bottom 25%
Balance sheet
Debt / equity 0.73× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.57× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 0.66× · Cheapest 25%
EV/EBITDA 23.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)64 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.49 $74.79 −28%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bluelinea SA · Fair Value
€0.3315 +58%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bluelinea SA Fair Value". https://www.fairvalue-calculator.com/stock/ALBLU

Frequently asked questions

Is Bluelinea SA (ALBLU) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €0.3315 versus a price of €0.1400, about +137% upside (undervalued).
What is the fair value of ALBLU?
Our model-based fair value for Bluelinea SA is €0.3315 (as of Sep 23, 2026), built from audited fundamentals. The current price: €0.1400.
What is the quality score of ALBLU?
Bluelinea SA has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bluelinea SA (ALBLU)?
Our model-based price target is the fair value of €0.3315 (as of Sep 23, 2026) from 2 valuation models. Cautious scenario €0.2210, optimistic scenario €0.4420. It is a calculation from audited fundamentals, not an analyst target.
What is the Bluelinea SA stock forecast for 2026?
Our models put fair value at €0.3315, about +137% upside versus a price of €0.1400 (undervalued). Cautious scenario €0.2210, optimistic scenario €0.4420. The calculation is refreshed regularly with new filings.
What is the revenue of Bluelinea SA (ALBLU)?
Bluelinea SA reported trailing-twelve-month revenue of about €11.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Bluelinea SA (ALBLU)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bluelinea SA it is €0.3315 per share (as of Sep 23, 2026), against a price of €0.1400. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Bluelinea SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, ALBLU trades below its calculated fair value: price €0.1400, fair value €0.3315, a gap of about +137% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALBLU?
No. The price is what the market pays today (€0.1400); the fair value is what the company's own numbers justify (€0.3315). For Bluelinea SA the two are €0.1915 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bluelinea SA worth?
The market values Bluelinea SA at about €6.4M (market capitalisation, as of Sep 23, 2026). Per share that is €0.1400; our models calculate a fair value of €0.3315 per share.
What do the bullish and bearish scenarios say about ALBLU?
Our models span a range for Bluelinea SA: cautious scenario €0.2210, base €0.3315, optimistic €0.4420 per share (as of Sep 23, 2026, price €0.1400). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Bluelinea SA (ALBLU)?
Balance-sheet figures for Bluelinea SA (as of Sep 23, 2026): return on equity −70.6%, debt of 0.73 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ALBLU from its 52-week high?
Bluelinea SA trades at €0.1400, about 74% below its 52-week high of €0.5305 and at the low of €0.1400 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3315 is for.
Which stocks are comparable to Bluelinea SA?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bluelinea SA stock attractive at the current price?
The data as of Sep 23, 2026: price €0.1400, calculated fair value €0.3315 (+137%), Quality Score 30/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALBLU calculated?
We run Bluelinea SA through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.3315, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Bluelinea SA currently trades 137 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bluelinea SA (ALBLU)?
The closing price on Sep 24, 2026 was €0.1400. Our model-based fair value is €0.3315, about +137% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bluelinea SA right now?
The large discount to fair value meets weak quality (30/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€0.2210). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.2210 to €0.4420) leaves room in how you read the outcome.

Key figures of Bluelinea SA

How large is the market capitalisation of Bluelinea SA (ALBLU)?
The market capitalisation of Bluelinea SA is €6.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bluelinea SA (ALBLU)?
The price-to-sales ratio of Bluelinea SA is 0.58 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bluelinea SA (ALBLU)?
Earnings per share at Bluelinea SA are €−0.0700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Bluelinea SA (ALBLU)?
The net margin of Bluelinea SA is −14.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bluelinea SA (ALBLU)?
The return on equity (ROE) of Bluelinea SA is −70.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bluelinea SA (ALBLU)?
On an EBIT basis the return on assets of Bluelinea SA is −17.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bluelinea SA (ALBLU)?
The operating margin of Bluelinea SA is −11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bluelinea SA (ALBLU)?
Revenue at Bluelinea SA is growing −8.9% versus a year earlier (3y avg 0.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Bluelinea SA (ALBLU) generate?
The free cash flow of Bluelinea SA is −€1.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bluelinea SA (ALBLU) carry?
The net debt of Bluelinea SA is €2.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bluelinea SA in the live analysis

One click puts Bluelinea SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.